Значение HER-2/NEU при раке желудка

1. Pyrhonen S, Kuitunen T, Nyandoto P et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995; 71: 587–91.
2. Kameda T, Yasui W, Yoshida K et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990; 50: 8002–9.
3. Jain S, Filipe M, Gullick W et al. C-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinomas: an immunohistochemical study on archival material. Int J Cancer 1991; 48: 668–71.
4. Yonemura Y, Ninomiya I, Oyohama S et al. Expression of cerbB-2 oncoprotein in gastric carcinoma. Cancer 1992; 67: 2914–8.
5. Ohguri T, Sato Y, Koizumi W et al. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 1993; 53: 75–9.
6. Lee E, Cibull M, Strodel W et al. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med 1994; 118: 235–9.
7. Tanner M et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273–8.
8. Park D et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371–9.
9. Yano T et al. Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 2004; 22: 14S.
10. Cortеs-Funes H. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. ASCO Annual Meeting 2007.
11. Nicholas G, Cripps C, Au H-P et al. Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2. ESMO 2006; 17 (Suppl. 9): 316.
12. Rech J, Arnold D, Folprecht G et al. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO 2006; 17 (Suppl. 9): 314.
13. Van Cutsem E. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). ASCO Ann Meet 2009; Abstr LBA4509.
14. Bang JT et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27: Abstr. 4556.
15. Gravalos C, Marquez A, Garcia-Carbonero R et al. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symposium 2007; 130: Abstr 89.
16. Lordick F, Bang YJ, Kang YK et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer 2007; 5 (4): 271.

А.Н.Луд, Ю.В.Вахабова, Н.Н.Семенов, И.П.Ганьшина, Е.В.Степанова

РОНЦ им. Н.Н.Блохина РАМН, г.Москва